Molly Sacks , Marieke Klein , Omar Shanta , Mohammad Ahangari , Oanh Hong , Jeff MacDonald , Bhooma Thiruvahindrapuram , Sebastien Jacquemont , Tim Bigdeli , Matthew Oetjens , Mart Kals , Stephen H. Scherer , Jonathan Sebat , The Bipolar Disorder, Schizophrenia, Post-Traumatic Stress Disorder, Attention-Deficit/Hyperactivity Disorder, Major Depressive Disorder, Autism Spectrum Disorder and Copy Number Variation working groups of the Psychiatric Genomics Consortium , Genes to Mental Health Network
{"title":"关于罕见 CNVs 和多基因风险对精神特征的综合影响的合作研究","authors":"Molly Sacks , Marieke Klein , Omar Shanta , Mohammad Ahangari , Oanh Hong , Jeff MacDonald , Bhooma Thiruvahindrapuram , Sebastien Jacquemont , Tim Bigdeli , Matthew Oetjens , Mart Kals , Stephen H. Scherer , Jonathan Sebat , The Bipolar Disorder, Schizophrenia, Post-Traumatic Stress Disorder, Attention-Deficit/Hyperactivity Disorder, Major Depressive Disorder, Autism Spectrum Disorder and Copy Number Variation working groups of the Psychiatric Genomics Consortium , Genes to Mental Health Network","doi":"10.1016/j.euroneuro.2024.08.072","DOIUrl":null,"url":null,"abstract":"<div><div>Recurrent CNVs are known to be major risk factors in neuropsychiatric disorders, yet phenotypic variability between carriers of the same CNV remains unexplained. A possible explanation is that the effect of a CNV depends on genetic background, which can be quantified by a polygenic risk score (PRS). Using data from the PGC and UKBB (combined n=543,111), this project aims to characterize the individual and combined effects of recurrent CNVs and PRS on six major psychiatric disorders: ADHD, ASD, BD, PTSD, MDD, and SCZ.</div><div>We first quantified the effects of 42 recurrent CNV loci across all 6 disorders using logistic regression. After Bonferroni correction, 24 loci had a significant association with at least one disorder in either the deletion or duplication. We next documented evidence for the traditional liability threshold model of disease risk; cases carrying CNVs with weak main effects had higher PRS than cases carrying CNVs with strong main effects. This pattern was strongest for SCZ (p=2.13e-4) but was evident in BD as well. Additionally, we tested a composite CNV-PRS model, which demonstrates how PRS can be a useful tool for predicting outcomes in CNV carriers. For example, a carrier of 16p11.2 proximal duplication (a well-known SCZ association) is not at increased risk for SCZ if they have a low PRS-SCZ.</div><div>To increase power to detect statistical interactions between CNVs and PRS, we conducted a meta-analysis of CNVxPRS effects on BMI and height in four biobanks: UK Biobank, Estonian Biobank, Geisinger Health, and Million Veterans Program, (n=975,408). Of the 32 CNVs that were sufficiently powered for this analysis (n > 225), 3 had nominally significant (p < .05) interactions with PRS on BMI. In all three cases, the sign on the interaction was the same as the main effect of the CNV, suggesting that these interactions are synergistic. When we collapsed CNVs by their main effect direction, we saw a significant negative interaction between the BMI decreasing CNVs and PRS (p=9.98e-4). These interactions were robust to rescaling of the BMI response variable via inverse normalization or Box-Cox. We observed no significant interactions for Height.</div><div>Taken together, these analyses demonstrate that the effect of recurrent CNVs is moderated by PRS. In addition to emphasizing the importance of considering genetic background when studying the effects of rare variants, this study also demonstrates that genetic factors may have non-additive effects on complex traits.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"87 ","pages":"Pages 28-29"},"PeriodicalIF":6.1000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"COLLABORATIVE STUDY OF THE COMBINED EFFECTS OF RARE CNVS AND POLYGENIC RISK ON PSYCHIATRIC TRAITS\",\"authors\":\"Molly Sacks , Marieke Klein , Omar Shanta , Mohammad Ahangari , Oanh Hong , Jeff MacDonald , Bhooma Thiruvahindrapuram , Sebastien Jacquemont , Tim Bigdeli , Matthew Oetjens , Mart Kals , Stephen H. Scherer , Jonathan Sebat , The Bipolar Disorder, Schizophrenia, Post-Traumatic Stress Disorder, Attention-Deficit/Hyperactivity Disorder, Major Depressive Disorder, Autism Spectrum Disorder and Copy Number Variation working groups of the Psychiatric Genomics Consortium , Genes to Mental Health Network\",\"doi\":\"10.1016/j.euroneuro.2024.08.072\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Recurrent CNVs are known to be major risk factors in neuropsychiatric disorders, yet phenotypic variability between carriers of the same CNV remains unexplained. A possible explanation is that the effect of a CNV depends on genetic background, which can be quantified by a polygenic risk score (PRS). Using data from the PGC and UKBB (combined n=543,111), this project aims to characterize the individual and combined effects of recurrent CNVs and PRS on six major psychiatric disorders: ADHD, ASD, BD, PTSD, MDD, and SCZ.</div><div>We first quantified the effects of 42 recurrent CNV loci across all 6 disorders using logistic regression. After Bonferroni correction, 24 loci had a significant association with at least one disorder in either the deletion or duplication. We next documented evidence for the traditional liability threshold model of disease risk; cases carrying CNVs with weak main effects had higher PRS than cases carrying CNVs with strong main effects. This pattern was strongest for SCZ (p=2.13e-4) but was evident in BD as well. Additionally, we tested a composite CNV-PRS model, which demonstrates how PRS can be a useful tool for predicting outcomes in CNV carriers. For example, a carrier of 16p11.2 proximal duplication (a well-known SCZ association) is not at increased risk for SCZ if they have a low PRS-SCZ.</div><div>To increase power to detect statistical interactions between CNVs and PRS, we conducted a meta-analysis of CNVxPRS effects on BMI and height in four biobanks: UK Biobank, Estonian Biobank, Geisinger Health, and Million Veterans Program, (n=975,408). Of the 32 CNVs that were sufficiently powered for this analysis (n > 225), 3 had nominally significant (p < .05) interactions with PRS on BMI. In all three cases, the sign on the interaction was the same as the main effect of the CNV, suggesting that these interactions are synergistic. When we collapsed CNVs by their main effect direction, we saw a significant negative interaction between the BMI decreasing CNVs and PRS (p=9.98e-4). These interactions were robust to rescaling of the BMI response variable via inverse normalization or Box-Cox. We observed no significant interactions for Height.</div><div>Taken together, these analyses demonstrate that the effect of recurrent CNVs is moderated by PRS. In addition to emphasizing the importance of considering genetic background when studying the effects of rare variants, this study also demonstrates that genetic factors may have non-additive effects on complex traits.</div></div>\",\"PeriodicalId\":12049,\"journal\":{\"name\":\"European Neuropsychopharmacology\",\"volume\":\"87 \",\"pages\":\"Pages 28-29\"},\"PeriodicalIF\":6.1000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Neuropsychopharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0924977X24002712\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Neuropsychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0924977X24002712","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
COLLABORATIVE STUDY OF THE COMBINED EFFECTS OF RARE CNVS AND POLYGENIC RISK ON PSYCHIATRIC TRAITS
Recurrent CNVs are known to be major risk factors in neuropsychiatric disorders, yet phenotypic variability between carriers of the same CNV remains unexplained. A possible explanation is that the effect of a CNV depends on genetic background, which can be quantified by a polygenic risk score (PRS). Using data from the PGC and UKBB (combined n=543,111), this project aims to characterize the individual and combined effects of recurrent CNVs and PRS on six major psychiatric disorders: ADHD, ASD, BD, PTSD, MDD, and SCZ.
We first quantified the effects of 42 recurrent CNV loci across all 6 disorders using logistic regression. After Bonferroni correction, 24 loci had a significant association with at least one disorder in either the deletion or duplication. We next documented evidence for the traditional liability threshold model of disease risk; cases carrying CNVs with weak main effects had higher PRS than cases carrying CNVs with strong main effects. This pattern was strongest for SCZ (p=2.13e-4) but was evident in BD as well. Additionally, we tested a composite CNV-PRS model, which demonstrates how PRS can be a useful tool for predicting outcomes in CNV carriers. For example, a carrier of 16p11.2 proximal duplication (a well-known SCZ association) is not at increased risk for SCZ if they have a low PRS-SCZ.
To increase power to detect statistical interactions between CNVs and PRS, we conducted a meta-analysis of CNVxPRS effects on BMI and height in four biobanks: UK Biobank, Estonian Biobank, Geisinger Health, and Million Veterans Program, (n=975,408). Of the 32 CNVs that were sufficiently powered for this analysis (n > 225), 3 had nominally significant (p < .05) interactions with PRS on BMI. In all three cases, the sign on the interaction was the same as the main effect of the CNV, suggesting that these interactions are synergistic. When we collapsed CNVs by their main effect direction, we saw a significant negative interaction between the BMI decreasing CNVs and PRS (p=9.98e-4). These interactions were robust to rescaling of the BMI response variable via inverse normalization or Box-Cox. We observed no significant interactions for Height.
Taken together, these analyses demonstrate that the effect of recurrent CNVs is moderated by PRS. In addition to emphasizing the importance of considering genetic background when studying the effects of rare variants, this study also demonstrates that genetic factors may have non-additive effects on complex traits.
期刊介绍:
European Neuropsychopharmacology is the official publication of the European College of Neuropsychopharmacology (ECNP). In accordance with the mission of the College, the journal focuses on clinical and basic science contributions that advance our understanding of brain function and human behaviour and enable translation into improved treatments and enhanced public health impact in psychiatry. Recent years have been characterized by exciting advances in basic knowledge and available experimental techniques in neuroscience and genomics. However, clinical translation of these findings has not been as rapid. The journal aims to narrow this gap by promoting findings that are expected to have a major impact on both our understanding of the biological bases of mental disorders and the development and improvement of treatments, ideally paving the way for prevention and recovery.